drugset / Trial / NCT07416032
A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia
Phase 0
Not yet recruiting
27 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Shanghai Xiniao Biotech Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells(QT-019C) in Patients With Refractory Primary Immune Thrombocytopenia.
Timeline
- Start
- 2026-02-20
- Primary completion
- 2028-06-20
- Completion
- 2029-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QT-019C | Cell therapy | 1e+06 cells/kg | Intravenous |